BIIB Stock Brushes Off Bull Note

Biogen also joined Behind The Seizure -- a group providing genetic testing to children under eight

Lillian Currens

Digital Content Manager

Jan 8, 2020 at 10:37 AM

BIIB

Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is slightly lower today, despite joining Behind the Seizure, along with a number of other companies, which works to provide faster diagnosis to children under eight with epilepsy. In addition to this, RBC lifted its price target to $285 from $267, which is still a slight discount to last night's close. At last check, BIIB is down 0.4% at $289.03.

Since its late-October bull gap, the stock has been contained by the $280 and $310 regions, with recent support emerging at the 60-day moving average. On the other hand, BIIB is pacing for its fifth straight loss and is down 10.7% year-over-year.

Analysts are still cautious on the stock, with 17 in coverage giving it a "hold" or worse rating, compared to only seven calling it a "strong buy." Plus, the consensus 12-month target price of $303.29 is just a slim 5.7% premium to current levels.

Follow @Schaeffers

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!